HA

HANNA AHMARIPOUR

AMERICAN ACADEMY OF NEUROLOGY · Washington, DC · registered since 2024
Registered · LDAActive

At a glance

Registered since
2024
Senate LDA system
Clients
1
last 3 years
Filings
3
4 agencies contacted
Activity
filings by quarter
Works on

Background

Government experience
Policy Intern
Senator Blumenthal; Policy Intern, Representative Himes
Disclosed on LD-2 filings
Career
Washington, DC
2024 - present

Specific issues

H.R. 2389: Resident Physician Shortage Reduction Act S. 665 / H.R. 4942: Conrad State 30 and Physician Access Reauthorization Act S. 704 / H.R. 1202: Resident Education Deferred Interest Act of 2021 H.R. 5435: Bringing Regulatory Advances into Neuroscience (BRAIN) Act  S. 652 / H.R. 2630 Safe Step Act Urging support for and the bolstering of the neurology workforce Urging reforms to proposed surprise billing regulations to align with congressional intent for payment disputes. Support for creating a Neuroscience Center of Excellence at FDA. Medical research funding related to NIH including the BRAIN Initiative, AHRQ, HEAL Initiative, and the Congressionally Directed Medical Research Programs at the Department of Defense. Support for funding for the Pediatric Subspecialty Loan Repayment Program Support for research related to Long COVID Improvements in the National Coverage Determination (NCD) process related to treatment for Alzheimer's disease Support for access to innovative treatments in the field of neurology that are both safe and effective Related issues impacting access to neurologic care
Health Issues · 2024 Q3
S. 368 / H.R. 1332: Telehealth Modernization Act S. 833 / H.R. 2071: Empowering Medicare Seniors to Negotiate Drug Prices Act S. 1512 / H.R. 2903: CONNECT for Health Act of 2021 H.R. 2474: Strengthening Medicare for Patients and Providers Act Improving Seniors Timely Access to Care Act Engagement with CMS regarding National Coverage Analysis (NCA) of monoclonal antibodies directed at amyloid beta plaque for the treatment of Alzheimers Disease. Support for a permanent expansion of telehealth in Medicare, including eliminating on originating site and geographic restrictions. Support for policies to address prescription drug costs, including supporting direct negotiation in Medicare, improving drug pricing transparency, and capping beneficiary out-of-pocket costs in Medicare Part D. Expressing concerns with Medicare physician payment Expressing concerns related to prior authorization Improvements in the National Coverage Determination (NCD) process related to treatment for Alzheimer's disease Support for access to innovative treatments in the field of neurology that are both safe and effective Support for implementation of proposed G2211 complexity add-on code in the MPFS Urging support for continued authority to prescribe medications through telehealth
Medicare/Medicaid · 2024 Q3
S. 652 / H.R. 2630 Safe Step Act
Insurance · 2024 Q3
Support for creating a Neuroscience Center of Excellence at FDA. Medical research funding related to NIH including the BRAIN Initiative, AHRQ, HEAL Initiative, and the Congressionally Directed Medical Research Programs at the Department of Defense. Support for increased funding for the VA Neurology Centers of Excellence, which include centers dedicated to Epilepsy, Multiple sclerosis, Headache, and Parkinsons disease.
Budget/Appropriations · 2024 Q3
Support for increased funding for the VA Neurology Centers of Excellence, which include centers dedicated to Epilepsy, Multiple sclerosis, Headache, and Parkinsons disease. Support for the VA Medical and Prosthetic Research Program.
Veterans · 2024 Q3
S. 368 / H.R. 1332: Telehealth Modernization Act S. 833 / H.R. 2071: Empowering Medicare Seniors to Negotiate Drug Prices Act S. 1512 / H.R. 2903: CONNECT for Health Act of 2021 H.R. 2474: Strengthening Medicare for Patients and Providers Act Improving Seniors Timely Access to Care Act Engagement with CMS regarding National Coverage Analysis (NCA) of monoclonal antibodies directed at amyloid beta plaque for the treatment of Alzheimers Disease. Support for a permanent expansion of telehealth in Medicare, including eliminating on originating site and geographic restrictions. Support for policies to address prescription drug costs, including supporting direct negotiation in Medicare, improving drug pricing transparency, and capping beneficiary out-of-pocket costs in Medicare Part D. Expressing concerns with Medicare physician payment Expressing concerns related to prior authorization Improvements in the National Coverage Determination (NCD) process related to treatment for Alzheimer's disease Support for access to innovative treatments in the field of neurology that are both safe and effective Support for implementation of proposed G2211 complexity add-on code in the MPFS
Medicare/Medicaid · 2024 Q2

Clients

$██,███ / qtrUnlock

Filing history

2024 Q3
AMERICAN ACADEMY OF NEUROLOGY
Q3lda.gov →
2024 Q2
AMERICAN ACADEMY OF NEUROLOGY
Q2lda.gov →
2024 Q1
AMERICAN ACADEMY OF NEUROLOGY
Q1lda.gov →
Showing recent filings · full history on lda.gov